The therapeutic classes that showed larger sales in Spain were nephrology, rheumatology and central nervous system, concentrating 40% of the total sales with Resincalcio (calcium polystyrene sulphonate), Dolquine (hydroxychloroquine) and Rubifen (methylphenidate), respectively. Rubifen was also one of the main drivers of the international growth of the company, increasing its sales 26%. In 2007 Rubió will enhance its national and international presence through partnerships with other companies. As a result, the company expects to maintain a double digit growth rate in sales in 2007.
Laboratorios Rubió will concentrate its efforts on strengthening its core therapeutic areas. Nowadays the company is leader in attention deficit hyperactivity disorder (ADHD) in Spain with Rubifen and has a significant presence in epilepsy, rheumatoid arthritis and hiperphosphataemia in patients with chronic kidney disease.
In 2007 Rubió will also increase its R+D activities, focusing them on the development of new formulations and indications of its main drugs.\
Changes in the Company At the end of 2006 Rubió strengthened its Management Board, with the appointment of Dr. Isabel Salvat as General Manager. Dr. Salvat is a Medicine Graduate and has held various management positions at both domestic and international levels in different pharmaceutical companies (ConvaTec, Almirall and Esteve, among others).
Laboratorios Rubió Laboratorios Rubió is a 100% Spanish company with almost 40 years of experience in the development, manufacturing and commercialization of medicines. Rubió always has been a pioneer company in launching drugs for diseases of low incidence. Thus it was the first company that made available in Spain a drug for treating ADHD -Rubifen-. In 2002 launched Dolquine, currently first-line therapy in mild-to-moderate lupus. www.laboratoriosrubio.es
